[Skip to Content]
[Skip to Content Landing]
Editorial
June 7, 2000

New Opportunities for Prevention of Meningococcal Disease

Author Affiliations

Author Affiliation: Division of Bacterial and Mycotic Diseases, Centers for Disease Control and Prevention, Atlanta, Ga.

JAMA. 2000;283(21):2842-2844. doi:10.1001/jama.283.21.2842

With near elimination of Haemophilus influenzae type b (Hib) disease through use of conjugate vaccines in many countries and newly available pneumococcal conjugates, prevention of meningococcal disease is an increasingly important priority for control of bacterial meningitis. The elegant meningococcal vaccine immunogenicity study by MacLennan and colleagues1 in this issue of THE JOURNAL is another example of how polysaccharide protein conjugation can overcome the immunologic shortcomings of plain polysaccharide vaccines in infants and young children.

First Page Preview View Large
First page PDF preview
First page PDF preview
×